Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Neoplasms of the CNS

  Free Subscription

Articles published in BMC Cancer

Retrieve available abstracts of 139 articles:
HTML format

Single Articles

    November 2022
  1. LIU X, Yang J, Li H, Wang Q, et al
    Quantifying substantial carcinogenesis of genetic and environmental factors from measurement error in the number of stem cell divisions.
    BMC Cancer. 2022;22:1194.
    PubMed     Abstract available

  2. ZHANG Y, Wang X, Shi M, Song Y, et al
    Programmed death ligand 1 and tumor-infiltrating CD8(+) T lymphocytes are associated with the clinical features in meningioma.
    BMC Cancer. 2022;22:1171.
    PubMed     Abstract available

    October 2022
  3. GALLITTO M, Savacool M, Lee A, Wang TJC, et al
    Feasibility of fractionated gamma knife radiosurgery in the management of newly diagnosed Glioblastoma.
    BMC Cancer. 2022;22:1095.
    PubMed     Abstract available

    September 2022
  4. CHEN Z, Zhou L, Zhao M, Cao K, et al
    Real-world analysis of different intracranial radiation therapies in non-small cell lung cancer patients with 1-4 brain metastases.
    BMC Cancer. 2022;22:1010.
    PubMed     Abstract available

  5. CHOI JM, Lim SH, Liu ZP, Lee TK, et al
    Flagellin synergistically enhances anti-tumor effect of EGFRvIII peptide in a glioblastoma-bearing mouse brain tumor model.
    BMC Cancer. 2022;22:986.
    PubMed     Abstract available

  6. TU Z, Ji Q, Han Q, Long X, et al
    Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas.
    BMC Cancer. 2022;22:973.
    PubMed     Abstract available

  7. WENDLER J, Fox CP, Valk E, Steinheber C, et al
    Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma.
    BMC Cancer. 2022;22:971.
    PubMed     Abstract available

    August 2022
  8. HUANG Y, Ouyang F, Yang F, Zhang N, et al
    The expression of Hexokinase 2 and its hub genes are correlated with the prognosis in glioma.
    BMC Cancer. 2022;22:900.
    PubMed     Abstract available

  9. YU H, Gong M, Qi J, Zhao C, et al
    Systematic transcriptome profiling of pyroptosis related signature for predicting prognosis and immune landscape in lower grade glioma.
    BMC Cancer. 2022;22:885.
    PubMed     Abstract available

  10. JIANG L, Yang J, Xu Q, Lv K, et al
    Machine learning for the micropeptide encoded by LINC02381 regulates ferroptosis through the glucose transporter SLC2A10 in glioblastoma.
    BMC Cancer. 2022;22:882.
    PubMed     Abstract available

  11. SCHULZ JA, Rodgers LT, Kryscio RJ, Hartz AMS, et al
    Characterization and comparison of human glioblastoma models.
    BMC Cancer. 2022;22:844.
    PubMed     Abstract available

  12. ROY C, Avril S, Legendre C, Lelievre B, et al
    A role for ceruloplasmin in the control of human glioblastoma cell responses to radiation.
    BMC Cancer. 2022;22:843.
    PubMed     Abstract available

    July 2022
  13. GUAN Y, Pan M, Yang J, Lu Q, et al
    A phase II open label, single arm study of hypofractionated stereotactic radiotherapy with chemoradiotherapy using intensity-modulated radiotherapy for newly diagnosed glioblastoma after surgery: the HSCK-010 trial protocol.
    BMC Cancer. 2022;22:827.
    PubMed     Abstract available

  14. YU J, Gao G, Wei X, Wang Y, et al
    TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma.
    BMC Cancer. 2022;22:786.
    PubMed     Abstract available

  15. ABUHAMED J, Nikkila A, Raitanen J, Alimam W, et al
    Incidence trends of childhood central nervous system tumors in Finland 1990-2017.
    BMC Cancer. 2022;22:784.
    PubMed     Abstract available

  16. WU X, Li C, Wang Z, Zhang Y, et al
    A bioinformatic analysis study of m(7)G regulator-mediated methylation modification patterns and tumor microenvironment infiltration in glioblastoma.
    BMC Cancer. 2022;22:729.
    PubMed     Abstract available

    June 2022
  17. LI JD, Farah AA, Huang ZG, Zhai GQ, et al
    Clinical significance and potential regulatory mechanism of overexpression of pituitary tumor-transforming gene transcription factor in bladder cancer.
    BMC Cancer. 2022;22:713.
    PubMed     Abstract available

  18. WANG J, Qiu X, Huang J, Zhuo Z, et al
    Development and validation of a novel mitophagy-related gene prognostic signature for glioblastoma multiforme.
    BMC Cancer. 2022;22:644.
    PubMed     Abstract available

  19. WICK A, Sander A, Koch M, Bendszus M, et al
    Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.
    BMC Cancer. 2022;22:645.
    PubMed     Abstract available

  20. MALA U, Baral TK, Somasundaram K
    Integrative analysis of cell adhesion molecules in glioblastoma identified prostaglandin F2 receptor inhibitor (PTGFRN) as an essential gene.
    BMC Cancer. 2022;22:642.
    PubMed     Abstract available

  21. DING MR, Qu YJ, Peng X, Chen JF, et al
    Pyroptosis-related prognosis model, immunocyte infiltration characterization, and competing endogenous RNA network of glioblastoma.
    BMC Cancer. 2022;22:611.
    PubMed     Abstract available

  22. GATELY L, Drummond K, Rosenthal M, Harrup R, et al
    Beyond standard data collection - the promise and potential of BRAIN (Brain tumour Registry Australia INnovation and translation registry).
    BMC Cancer. 2022;22:604.
    PubMed     Abstract available

    May 2022
  23. YANG H, Wen L, Pan Y, Shan C, et al
    Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing.
    BMC Cancer. 2022;22:580.
    PubMed     Abstract available

  24. XU X, Yuan H, Pan J, Chen W, et al
    The identification of miRNA and mRNA expression profiles associated with pediatric atypical teratoid/rhabdoid tumor.
    BMC Cancer. 2022;22:499.
    PubMed     Abstract available

  25. FISCHER GF, Brugge D, Andratschke N, Baumert BG, et al
    Postoperative radiotherapy for meningiomas - a decision-making analysis.
    BMC Cancer. 2022;22:492.
    PubMed     Abstract available

    April 2022
  26. KOOPAIE M, Ghafourian M, Manifar S, Younespour S, et al
    Evaluation of CSTB and DMBT1 expression in saliva of gastric cancer patients and controls.
    BMC Cancer. 2022;22:473.
    PubMed     Abstract available

  27. LI J, Wang J, Ding Y, Zhao J, et al
    Prognostic biomarker SGSM1 and its correlation with immune infiltration in gliomas.
    BMC Cancer. 2022;22:466.
    PubMed     Abstract available

  28. ZHANG J, Guo Z, Xie Q, Zhong C, et al
    Tryptophan hydroxylase 1 drives glioma progression by modulating the serotonin/L1CAM/NF-kappaB signaling pathway.
    BMC Cancer. 2022;22:457.
    PubMed     Abstract available

  29. KLEINBERGER I, Sanders E, Staes K, Van Troys M, et al
    Innovative mouse models for the tumor suppressor activity of Protocadherin-10 isoforms.
    BMC Cancer. 2022;22:451.
    PubMed     Abstract available

  30. ARUNACHALAM E, Rogers W, Simpson GR, Moller-Levet C, et al
    HOX and PBX gene dysregulation as a therapeutic target in glioblastoma multiforme.
    BMC Cancer. 2022;22:400.
    PubMed     Abstract available

  31. WANG C, Liu C, Chen J, Jiang H, et al
    Effect of neoadjuvant iodine-125 brachytherapy upon resection of glioma.
    BMC Cancer. 2022;22:397.
    PubMed     Abstract available

  32. BELANGER K, Ung TH, Damek D, Lillehei KO, et al
    Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review.
    BMC Cancer. 2022;22:367.
    PubMed     Abstract available

    March 2022
  33. RYDEN I, Thurin E, Carstam L, Smits A, et al
    Correction: Psychotropic and anti-epileptic drug use, before and after surgery, among patients with low-grade glioma: a nationwide matched cohort study.
    BMC Cancer. 2022;22:350.

  34. SANDER C, Frydrychowicz C, Prasse G, Taubenheim S, et al
    The impact of neurological performance and volumetrics on overall survival in brain metastasis in colorectal cancer: a retrospective single-center case series.
    BMC Cancer. 2022;22:336.
    PubMed     Abstract available

  35. HESSLER N, Junger ST, Meissner AK, Kocher M, et al
    Recurrent brain metastases: the role of resection of in a comprehensive multidisciplinary treatment setting.
    BMC Cancer. 2022;22:275.
    PubMed     Abstract available

  36. EGGEN AC, Hospers GAP, Bosma I, Kramer MCA, et al
    Anti-tumor treatment and healthcare consumption near death in the era of novel treatment options for patients with melanoma brain metastases.
    BMC Cancer. 2022;22:247.
    PubMed     Abstract available

  37. BI Y, Wu ZH, Cao F
    Prognostic value and immune relevancy of a combined autophagy-, apoptosis- and necrosis-related gene signature in glioblastoma.
    BMC Cancer. 2022;22:233.
    PubMed     Abstract available

  38. PUHAKKA I, Kuitunen H, Jakala P, Sonkajarvi E, et al
    Primary central nervous system lymphoma high incidence and poor survival in Finnish population-based analysis.
    BMC Cancer. 2022;22:236.
    PubMed     Abstract available

  39. LI C, Liu F, Sun L, Liu Z, et al
    Natural killer cell-related gene signature predicts malignancy of glioma and the survival of patients.
    BMC Cancer. 2022;22:230.
    PubMed     Abstract available

    February 2022
  40. MOU Y, Zhang L, Liu Z, Song X, et al
    Abundant expression of ferroptosis-related SAT1 is related to unfavorable outcome and immune cell infiltration in low-grade glioma.
    BMC Cancer. 2022;22:215.
    PubMed     Abstract available

  41. WANG X, Wang Y, Xie F, Song ZT, et al
    Norepinephrine promotes glioma cell migration through up-regulating the expression of Twist1.
    BMC Cancer. 2022;22:213.
    PubMed     Abstract available

  42. FU J, Zeng J, Huang M, Liang S, et al
    Primary versus postoperative gamma knife radiosurgery for intracranial benign meningiomas: a matched cohort retrospective study.
    BMC Cancer. 2022;22:206.
    PubMed     Abstract available

  43. ZENG Y, Guo T, Zhou Y, Zhao Y, et al
    Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters.
    BMC Cancer. 2022;22:198.
    PubMed     Abstract available

  44. ZHANG X, Wu Y, Sun X, Cui Q, et al
    The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.
    BMC Cancer. 2022;22:190.
    PubMed     Abstract available

  45. BUENO-MARTINEZ E, Lara-Almunia M, Rodriguez-Arias C, Otero-Rodriguez A, et al
    Polymorphisms in autophagy genes are genetic susceptibility factors in glioblastoma development.
    BMC Cancer. 2022;22:146.
    PubMed     Abstract available

  46. TRIPATHI PH, Akhtar J, Arora J, Saran RK, et al
    Quantitative proteomic analysis of GnRH agonist treated GBM cell line LN229 revealed regulatory proteins inhibiting cancer cell proliferation.
    BMC Cancer. 2022;22:133.
    PubMed     Abstract available

    January 2022
  47. WEI R, Zhao C, Li J, Yang F, et al
    Online calculator to predict early mortality in patient with surgically treated recurrent lower-grade glioma.
    BMC Cancer. 2022;22:114.
    PubMed     Abstract available

  48. MAO XG, Xue XY, Wang L, Lin W, et al
    Deep learning identified glioblastoma subtypes based on internal genomic expression ranks.
    BMC Cancer. 2022;22:86.
    PubMed     Abstract available

  49. REN J, Zhang X, Cao J, Tian J, et al
    Radiosynthesis of a novel antisense imaging probe targeting LncRNA HOTAIR in malignant glioma.
    BMC Cancer. 2022;22:79.
    PubMed     Abstract available

  50. SCHAFF LR, Lobbous M, Carlow D, Schofield R, et al
    Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study.
    BMC Cancer. 2022;22:60.
    PubMed     Abstract available

  51. HOSEINI B, Rahmatinejad Z, Goshayeshi L, Bergquist R, et al
    Colorectal Cancer in North-Eastern Iran: a retrospective, comparative study of early-onset and late-onset cases based on data from the Iranian hereditary colorectal cancer registry.
    BMC Cancer. 2022;22:48.
    PubMed     Abstract available

  52. ALVAREZ-TORRES MDM, Fuster-Garcia E, Juan-Albarracin J, Reynes G, et al
    Local detection of microvessels in IDH-wildtype glioblastoma using relative cerebral blood volume: an imaging marker useful for astrocytoma grade 4 classification.
    BMC Cancer. 2022;22:40.
    PubMed     Abstract available

    December 2021
  53. RAYMOND P, Klein M, Cuny T, Klein O, et al
    High prevalence of anterior pituitary deficiencies after cranial radiation therapy for skull base meningiomas.
    BMC Cancer. 2021;21:1346.
    PubMed     Abstract available

  54. ZHANG M, Cheng Y, Xue Z, Sun Q, et al
    A novel pyroptosis-related gene signature predicts the prognosis of glioma through immune infiltration.
    BMC Cancer. 2021;21:1311.
    PubMed     Abstract available

    November 2021
  55. MACHARIA LW, Muriithi W, Heming CP, Nyaga DK, et al
    The genotypic and phenotypic impact of hypoxia microenvironment on glioblastoma cell lines.
    BMC Cancer. 2021;21:1248.
    PubMed     Abstract available

  56. POON MTC, Bruce M, Simpson JE, Hannan CJ, et al
    Temozolomide sensitivity of malignant glioma cell lines - a systematic review assessing consistencies between in vitro studies.
    BMC Cancer. 2021;21:1240.
    PubMed     Abstract available

  57. WEN J, Rusch M, Brady SW, Shao Y, et al
    The landscape of coding RNA editing events in pediatric cancer.
    BMC Cancer. 2021;21:1233.
    PubMed     Abstract available

  58. XIE H, Yuan C, Ding XH, Li JJ, et al
    Identification of key genes and pathways associated with resting mast cells in meningioma.
    BMC Cancer. 2021;21:1209.
    PubMed     Abstract available

  59. DJUZENOVA CS, Fischer T, Katzer A, Sisario D, et al
    Opposite effects of the triple target (DNA-PK/PI3K/mTOR) inhibitor PI-103 on the radiation sensitivity of glioblastoma cell lines proficient and deficient in DNA-PKcs.
    BMC Cancer. 2021;21:1201.
    PubMed     Abstract available

  60. SU X, Yang Y, Yang Q, Pang B, et al
    NOX4-derived ROS-induced overexpression of FOXM1 regulates aerobic glycolysis in glioblastoma.
    BMC Cancer. 2021;21:1181.
    PubMed     Abstract available

  61. XIE Y, Gong C, Zhang J, Wang L, et al
    Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases.
    BMC Cancer. 2021;21:1174.
    PubMed     Abstract available

    October 2021
  62. TONNEAU M, Mouttet-Audouard R, Le Tinier F, Mirabel X, et al
    Stereotactic body radiotherapy for intramedullary metastases: a retrospective series at the Oscar Lambret center and a systematic review.
    BMC Cancer. 2021;21:1168.
    PubMed     Abstract available

  63. ARAKAWA Y, Sasaki K, Mineharu Y, Uto M, et al
    A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII).
    BMC Cancer. 2021;21:1105.
    PubMed     Abstract available

  64. KEMMERER CL, Schittenhelm J, Dubois E, Neumann L, et al
    Cerebrospinal fluid cytokine levels are associated with macrophage infiltration into tumor tissues of glioma patients.
    BMC Cancer. 2021;21:1108.
    PubMed     Abstract available

  65. LIU R, Dai W, Wu A, Li Y, et al
    CircCDC45 promotes the malignant progression of glioblastoma by modulating the miR-485-5p/CSF-1 axis.
    BMC Cancer. 2021;21:1090.
    PubMed     Abstract available

    September 2021
  66. CHENG S, Yang L, Dai X, Wang J, et al
    The risk and prognostic factors for brain metastases in esophageal cancer patients: an analysis of the SEER database.
    BMC Cancer. 2021;21:1057.
    PubMed     Abstract available

  67. MAKINO Y, Arakawa Y, Yoshioka E, Shofuda T, et al
    Infrequent RAS mutation is not associated with specific histological phenotype in gliomas.
    BMC Cancer. 2021;21:1025.
    PubMed     Abstract available

  68. TYLDESLEY-MARSHALL N, Greenfield S, Neilson SJ, English M, et al
    The role of Magnetic Resonance Images (MRIs) in coping for patients with brain tumours and their parents: a qualitative study.
    BMC Cancer. 2021;21:1013.
    PubMed     Abstract available

  69. MIKIC N, Poulsen FR, Kristoffersen KB, Laursen RJ, et al
    Study protocol for OptimalTTF-2: enhancing Tumor Treating Fields with skull remodeling surgery for first recurrence glioblastoma: a phase 2, multi-center, randomized, prospective, interventional trial.
    BMC Cancer. 2021;21:1010.
    PubMed     Abstract available

    August 2021
  70. HACKSHAW MD, Danysh HE, Henderson M, Wang E, et al
    Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review.
    BMC Cancer. 2021;21:967.
    PubMed     Abstract available

  71. LI Y, Guo D
    Genome-wide profiling of alternative splicing in glioblastoma and their clinical value.
    BMC Cancer. 2021;21:958.
    PubMed     Abstract available

  72. KIM YJ, Oh H, Lee SJ, Kim KM, et al
    Prognostic significance of the postoperative prognostic nutritional index in patients with glioblastoma: a retrospective study.
    BMC Cancer. 2021;21:942.
    PubMed     Abstract available

  73. XIAO J, Xu L, Ding Y, Wang W, et al
    Does post-operative radiotherapy improve the treatment outcomes of intracranial hemangiopericytoma? A retrospective study.
    BMC Cancer. 2021;21:915.
    PubMed     Abstract available

    July 2021
  74. WANG X, Cai J, Zeng Z, Liu A, et al
    Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study.
    BMC Cancer. 2021;21:873.
    PubMed     Abstract available

  75. GINZAC A, Dupic G, Brun L, Molnar I, et al
    Preoperative stereotactic radiosurgery for brain metastases: the STEP study protocol for a multicentre, prospective, phase-II trial.
    BMC Cancer. 2021;21:864.
    PubMed     Abstract available

  76. ASANO K, Fumoto T, Matsuzaka M, Hasegawa S, et al
    Combination chemoradiotherapy with temozolomide, vincristine, and interferon-beta might improve outcomes regardless of O6-methyl-guanine-DNA-methyltransferase (MGMT) promoter methylation status in newly glioblastoma.
    BMC Cancer. 2021;21:867.
    PubMed     Abstract available

  77. SYAFRUDDIN SE, Nazarie WFWM, Moidu NA, Soon BH, et al
    Integration of RNA-Seq and proteomics data identifies glioblastoma multiforme surfaceome signature.
    BMC Cancer. 2021;21:850.
    PubMed     Abstract available

  78. HUANG T, Chen Y, Zeng Y, Xu C, et al
    Long non-coding RNA PSMA3-AS1 promotes glioma progression through modulating the miR-411-3p/HOXA10 pathway.
    BMC Cancer. 2021;21:844.
    PubMed     Abstract available

  79. ZHANG F, He Q, Luo G, Long Y, et al
    The combination of (13)N-ammonia and (11)C-methionine in differentiation of residual/recurrent pituitary adenoma from the pituitary gland remnant after trans-sphenoidal Adenomectomy.
    BMC Cancer. 2021;21:837.
    PubMed     Abstract available

  80. SHEN H, Deng G, Chen Q, Qian J, et al
    The incidence, risk factors and predictive nomograms for early death of lung cancer with synchronous brain metastasis: a retrospective study in the SEER database.
    BMC Cancer. 2021;21:825.
    PubMed     Abstract available

    June 2021
  81. SCHEICHEL F, Marhold F, Pinggera D, Kiesel B, et al
    Influence of preoperative corticosteroid treatment on rate of diagnostic surgeries in primary central nervous system lymphoma: a multicenter retrospective study.
    BMC Cancer. 2021;21:754.
    PubMed     Abstract available

  82. LU J, Peng Y, Huang R, Feng Z, et al
    Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    BMC Cancer. 2021;21:723.
    PubMed     Abstract available

  83. TU Z, Xiong H, Qiu Y, Li G, et al
    Limited recurrence distance of glioblastoma under modern radiotherapy era.
    BMC Cancer. 2021;21:720.
    PubMed     Abstract available

  84. ZHU W, Zhao H, Xu F, Huang B, et al
    The lipid-lowering drug fenofibrate combined with si-HOTAIR can effectively inhibit the proliferation of gliomas.
    BMC Cancer. 2021;21:664.
    PubMed     Abstract available

  85. MOON HH, Kim HS, Park JE, Kim YH, et al
    Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
    BMC Cancer. 2021;21:654.
    PubMed     Abstract available

    May 2021
  86. SHAN Q, Shi J, Wang X, Guo J, et al
    A new nomogram and risk classification system for predicting survival in small cell lung cancer patients diagnosed with brain metastasis: a large population-based study.
    BMC Cancer. 2021;21:640.
    PubMed     Abstract available

  87. ZHU J, Wang H, Sun Q, Ji X, et al
    Correction to: Nrf2 is required to maintain the self-renewal of glioma stem cells.
    BMC Cancer. 2021;21:582.

  88. MILLS MN, Naz A, Thawani C, Walker C, et al
    Capecitabine and stereotactic radiation in the management of breast cancer brain metastases.
    BMC Cancer. 2021;21:552.
    PubMed     Abstract available

  89. MAJCHRZAK-CELINSKA A, Misiorek JO, Kruhlenia N, Przybyl L, et al
    COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/beta-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
    BMC Cancer. 2021;21:493.
    PubMed     Abstract available

    April 2021
  90. YAMAMURA J, Kamigaki S, Fujita J, Osato H, et al
    New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
    BMC Cancer. 2021;21:476.
    PubMed     Abstract available

  91. XU B, Huo Z, Huang H, Ji W, et al
    The expression and prognostic value of the epidermal growth factor receptor family in glioma.
    BMC Cancer. 2021;21:451.
    PubMed     Abstract available

  92. AMIN S, Baine M, Meza J, Lin C, et al
    The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type.
    BMC Cancer. 2021;21:387.
    PubMed     Abstract available

  93. RADES D, Witteler J, Olbrich D, Trillenberg P, et al
    A prospective interventional study evaluating seizure activity during a radiotherapy course for high-grade gliomas (SURF-ROGG).
    BMC Cancer. 2021;21:386.
    PubMed     Abstract available

    March 2021
  94. KUO CS, Tung PH, Huang AC, Wang CC, et al
    A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
    BMC Cancer. 2021;21:309.
    PubMed     Abstract available

  95. XI J, Hassan B, Katumba RGN, Khaddour K, et al
    The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma.
    BMC Cancer. 2021;21:285.
    PubMed     Abstract available

  96. KIANG KM, Chan AA, Leung GK
    Secondary gliosarcoma: the clinicopathological features and the development of a patient-derived xenograft model of gliosarcoma.
    BMC Cancer. 2021;21:265.
    PubMed     Abstract available

  97. ZHANG C, Liu H, Xu P, Tan Y, et al
    Identification and validation of a five-lncRNA prognostic signature related to Glioma using bioinformatics analysis.
    BMC Cancer. 2021;21:251.
    PubMed     Abstract available

  98. RYDEN I, Thurin E, Carstam L, Smits A, et al
    Psychotropic and anti-epileptic drug use, before and after surgery, among patients with low-grade glioma: a nationwide matched cohort study.
    BMC Cancer. 2021;21:248.
    PubMed     Abstract available

  99. MILLS MN, Walker C, Thawani C, Naz A, et al
    Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases.
    BMC Cancer. 2021;21:223.
    PubMed     Abstract available

  100. MASALHA W, Daka K, Woerner J, Pompe N, et al
    Metabolic alterations in meningioma reflect the clinical course.
    BMC Cancer. 2021;21:211.
    PubMed     Abstract available

    February 2021
  101. ZHANG Y, Zou D, Yin J, Zhang L, et al
    Changes in cerebrospinal fluid interleukin-10 levels display better performance in predicting disease relapse than conventional magnetic resonance imaging in primary central nervous system lymphoma.
    BMC Cancer. 2021;21:183.
    PubMed     Abstract available

  102. KHAN M, Zhao Z, Arooj S, Liao G, et al
    Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis.
    BMC Cancer. 2021;21:167.
    PubMed     Abstract available

  103. KEOGH RJ, Aslam R, Hennessy MA, Coyne Z, et al
    One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.
    BMC Cancer. 2021;21:140.
    PubMed     Abstract available

  104. GUAN Y, Xiong J, Pan M, Shi W, et al
    Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience.
    BMC Cancer. 2021;21:123.
    PubMed     Abstract available

    January 2021
  105. LIU G, Liu D, Huang J, Li J, et al
    Comprehensive analysis of ceRNA network related to lincRNA in glioblastoma and prediction of clinical prognosis.
    BMC Cancer. 2021;21:98.
    PubMed     Abstract available

  106. LIU FM, Gao YF, Kong Y, Guan Y, et al
    The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET.
    BMC Cancer. 2021;21:83.
    PubMed     Abstract available

  107. WEN J, Chen W, Zhu Y, Zhang P, et al
    Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis.
    BMC Cancer. 2021;21:81.
    PubMed     Abstract available

  108. CHEN B, Chen C, Zhang Y, Xu J, et al
    Recent incidence trend of elderly patients with glioblastoma in the United States, 2000-2017.
    BMC Cancer. 2021;21:54.
    PubMed     Abstract available

  109. WANG Y, Zhang Y, Hong Y, Zeng P, et al
    Advance directives and end-of-life care: knowledge and preferences of patients with brain Tumours from Anhui, China.
    BMC Cancer. 2021;21:25.
    PubMed     Abstract available

    December 2020
  110. HIGGINS DMO, Caliva M, Schroeder M, Carlson B, et al
    Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas.
    BMC Cancer. 2020;20:1213.
    PubMed     Abstract available

  111. COLLINS DC, Sundar R, Constantinidou A, Dolling D, et al
    Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease.
    BMC Cancer. 2020;20:1210.
    PubMed     Abstract available

    November 2020
  112. YU X, Wang Y, Yuan Z, Yu H, et al
    Benefit of dosimetry distribution for patients with multiple brain metastases from non-small cell lung cancer by a Cyberknife stereotactic radiosurgery (SRS) system.
    BMC Cancer. 2020;20:1144.
    PubMed     Abstract available

  113. LI X, Meng Y
    Analyses of metastasis-associated genes in IDH wild-type glioma.
    BMC Cancer. 2020;20:1114.
    PubMed     Abstract available

  114. ZHU Z, Lan Y, Wang L, Ge J, et al
    A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    BMC Cancer. 2020;20:1072.
    PubMed     Abstract available

  115. AFTAHY AK, Barz M, Krauss P, Liesche F, et al
    Intraventricular neuroepithelial tumors: surgical outcome, technical considerations and review of literature.
    BMC Cancer. 2020;20:1060.
    PubMed     Abstract available

    October 2020
  116. CHIA BSH, Leong JY, Ong ALK, Lim C, et al
    Randomised prospective phase II trial in multiple brain metastases comparing outcomes between hippocampal avoidance whole brain radiotherapy with or without simultaneous integrated boost: HA-SIB-WBRT study protocol.
    BMC Cancer. 2020;20:1045.
    PubMed     Abstract available

  117. DING X, Yang L, Geng X, Zou Y, et al
    CircRNAs as potential biomarkers for the clinicopathology and prognosis of glioma patients: a meta-analysis.
    BMC Cancer. 2020;20:1005.
    PubMed     Abstract available

  118. GUENOLE M, Lucia F, Bourbonne V, Dissaux G, et al
    Impact of concomitant systemic treatments on toxicity and intracerebral response after stereotactic radiotherapy for brain metastases.
    BMC Cancer. 2020;20:991.
    PubMed     Abstract available

  119. FENG J, Ouyang Y, Xu D, He Q, et al
    Genetic variants in MIR17HG affect the susceptibility and prognosis of glioma in a Chinese Han population.
    BMC Cancer. 2020;20:976.
    PubMed     Abstract available

  120. HONG KT, Lee DH, Kim BK, An HY, et al
    Treatment outcome and long-term follow-up of central nervous system germ cell tumor using upfront chemotherapy with subsequent photon or proton radiation therapy: a single tertiary center experience of 127 patients.
    BMC Cancer. 2020;20:979.
    PubMed     Abstract available

  121. BLECKMANN A, Kirchner B, Nietert M, Peeck M, et al
    Impact of pre-OP independence in patients with limited brain metastases on long-term survival.
    BMC Cancer. 2020;20:973.
    PubMed     Abstract available

    September 2020
  122. WANG J, Tong L, Lin G, Wang H, et al
    Immunological and clinicopathological characteristics of C1RL in 2120 glioma patients.
    BMC Cancer. 2020;20:931.
    PubMed     Abstract available

  123. DU F, Hou Q
    SNHG17 drives malignant behaviors in astrocytoma by targeting miR-876-5p/ERLIN2 axis.
    BMC Cancer. 2020;20:839.
    PubMed     Abstract available

    August 2020
  124. COSTE A, Bailey HD, Kartal-Kaess M, Renella R, et al
    Parental occupational exposure to pesticides and risk of childhood cancer in Switzerland: a census-based cohort study.
    BMC Cancer. 2020;20:819.
    PubMed     Abstract available

  125. HEILAND DH, Ohle R, Cipriani D, Franco P, et al
    Characterization of longitudinal transformation of T2-hyperintensity in oligodendroglioma.
    BMC Cancer. 2020;20:818.
    PubMed     Abstract available

    July 2020
  126. LOCSEI Z, Farkas R, Borbasne Farkas K, Sebestyen K, et al
    Assessment of the results and hematological side effects of 3D conformal and IMRT/ARC therapies delivered during craniospinal irradiation of childhood tumors with a follow-up period of five years.
    BMC Cancer. 2020;20:702.
    PubMed     Abstract available

  127. ZHAO Y, He JY, Cui JZ, Meng ZQ, et al
    Detection of genes mutations in cerebrospinal fluid circulating tumor DNA from neoplastic meningitis patients using next generation sequencing.
    BMC Cancer. 2020;20:690.
    PubMed     Abstract available

  128. LIN J, Yu L, Fu Y, Chen H, et al
    A refractory case of CDK4-amplified spinal astrocytoma achieving complete response upon treatment with a Palbociclib-based regimen:a case report.
    BMC Cancer. 2020;20:630.
    PubMed     Abstract available

  129. MEZEI T, Hajdu M, Czigleczki G, Lotz G, et al
    Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: a case report and literature review.
    BMC Cancer. 2020;20:615.
    PubMed     Abstract available

    June 2020
  130. MEHTA P, Janssen S, Fahlbusch FB, Schmid SM, et al
    Sparing the hippocampus and the hypothalamic- pituitary region during whole brain radiotherapy: a volumetric modulated arc therapy planning study.
    BMC Cancer. 2020;20:610.
    PubMed     Abstract available

  131. XU T, Zhang X, Zhang S, Liu C, et al
    Imaging features and prognostic value of (18)F-FDG PET/CT detection of soft-tissue metastasis from lung cancer: a retrospective study.
    BMC Cancer. 2020;20:596.
    PubMed     Abstract available

  132. GROSU AL, Frings L, Bentsalo I, Oehlke O, et al
    Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) - a phase II prospective randomized multicenter trial (NOA-14, ARO 2015-3, DKTK-ROG).
    BMC Cancer. 2020;20:532.
    PubMed     Abstract available

  133. DEVECKA M, Duma MN, Wilkens JJ, Kampfer S, et al
    Craniospinal irradiation(CSI) in patients with leptomeningeal metastases: risk-benefit-profile and development of a prognostic score for decision making in the palliative setting.
    BMC Cancer. 2020;20:501.
    PubMed     Abstract available

    May 2020
  134. BUCKSCH K, Zachariae S, Aretz S, Buttner R, et al
    Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort study.
    BMC Cancer. 2020;20:460.
    PubMed     Abstract available

  135. WAKUDA K, Yamaguchi H, Kenmotsu H, Fukuda M, et al
    A phase II study of Osimertinib for patients with radiotherapy-naive CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L).
    BMC Cancer. 2020;20:370.
    PubMed     Abstract available

    April 2020
  136. FURUSE M, Kuwabara H, Ikeda N, Hattori Y, et al
    PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
    BMC Cancer. 2020;20:277.
    PubMed     Abstract available

    March 2020
  137. NAWROCKI S, Sugajska A
    Study protocol: watchful observation of patients with limited small cell lung cancer instead of the PCI-prospective, multi-center one-arm study.
    BMC Cancer. 2020;20:231.
    PubMed     Abstract available

    February 2020
  138. CHO I, Lee H, Yoon SE, Ryu KJ, et al
    Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
    BMC Cancer. 2020;20:120.
    PubMed     Abstract available

  139. TREUTWEIN M, Steger F, Loeschel R, Koelbl O, et al
    The influence of radiotherapy techniques on the plan quality and on the risk of secondary tumors in patients with pituitary adenoma.
    BMC Cancer. 2020;20:88.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.